High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration

American Journal of Hematology

Volumn 51, Issue 1, 1996, Pages 90-92

  Lombardo, Turiddu ^a   Ferro, Gabriella ^a   Frontini, Viviana ^a   Percolla, Sebastiane ^b  

^a Ospedale Ferrarotto   (Italy)

^b Clinica Specializzata Gretter   (Italy)

Author keywords

Allergy to subcutaneous DFO; Desferrioxamine (DFO); High dose infusion chelating therapy; Iron overload; Thalassemia

Indexed keywords

DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CHELATION THERAPY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON OVERLOAD; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CATHETERS, INDWELLING; CHELATION THERAPY; DEFEROXAMINE; DRUG HYPERSENSITIVITY; FEMALE; FERRITINS; HEMOCHROMATOSIS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; MALE; SIDEROPHORES;

EID: 0030069985     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199601)51:1<90::AID-AJH15>3.0.CO;2-F     Document Type: Article

References (10)

1. De Montalembert M, Jan D, Clairicia M, Hannedouche T, Sidi D, Girot R: Intensification du traitement chèlateur du fer par la desferrioxamine à l'aide d'une chambre implantable d'accès veineux (Port-a-Cath). Arch Fr Pediatr 49:159-163, 1992.
2. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S: Survival and causes of death in thalassemia major. Lancet 2:27-30, 1989.
3. Cohen A: Current status of iron chelation therapy with deferoxamine. Semin Hematol 27:86-90, 1990.
4. Cohen A, Mizanin J, Schwartz E: Rapid removal of excessive iron with daily, high dose intravenous chelatson therapy. J Pediatr 1:151-155, 1989.
5. Wonke B, Fielding A: Novel delivery system for continuous desferrioxamine infusion in iron-overloaded patients. Lancet 340:790-791, 1992.
6. Kirking MH: Treatment of cronic iron overload. Clin Pharm 10:775-783, 1991.
7. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH: Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia mayor. N Engl J Med. 312:1600-1603, 1985.
8. Shalit M, Tedeschi A, Miadonna A, Levi-Shaffer A: Desferal (desferrioxamine) - A novel activator of connective tissue-type mast cells. J Allergy Clin Immunol 6:854-860, 1991.
9. Tamary H, Goshen J, Carmi D, Yaniv I, Kaplinsky C, Cohen I, Zaizov R. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients. Isr J Med Sci 30:658-664, 1994.
10. Bousquet J, Navarro M, Robert G, Aye P, Michel FB: Rapid desensitisation for desferrioxamine anaphylactoid reactions. Lancet 2:859-860, 1983.